Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Halcinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 1.00 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Halcinonide SCHEMBL5188866 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL10019829 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL13026159 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL4335 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL4336 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL24015431 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL8467031 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL5489567 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL8529770 | 0.99 | NR3C1 (0.98) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL2843940 | 0.99 | NR3C1 (0.98) | NR3C1PGRCYP3A4ARUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160773-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2021-11-02 | — | — | US | disclosed |
| US-20200246282-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2020-08-06 | — | — | US | disclosed |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2020-05-19 | — | — | US | disclosed |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2018-07-24 | — | — | US | disclosed |
| US-8124597-B2 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-28 | — | — | US | disclosed |
| US-20090075960-A1 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075960-A1 | Method of treating gaucher disease | GBA1, GAA, GBA3 | NR3C1 2810/4885PGR 4793/4885CYP3A4 4590/4885 |
| US-20200246282-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | GBA1, GBA3, GAA | NR3C1 3825/4885PGR 4842/4885CYP3A4 4270/4885 |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | NR3C1 3825/4885PGR 4842/4885CYP3A4 4270/4885 |
| US-11160773-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | NR3C1 3825/4885PGR 4842/4885CYP3A4 4270/4885 |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | NR3C1 3825/4885PGR 4842/4885CYP3A4 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.